Pregled bibliografske jedinice broj: 522544
Detection of BCR/ABL1 translocation in CML using FISH
Detection of BCR/ABL1 translocation in CML using FISH // Chromosome Research / Garcia-Sagredo, Jose ; Madan, Kamlesh ; Miller KOnstantin (ur.).
Dordrecht: Springer, 2011. str. S144-S144 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 522544 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Detection of BCR/ABL1 translocation in CML using FISH
Autori
Korać, Petra ; Kardum Paro, Mirjana Mariana ; Lasan Trčić, Ružica ; Ostojić Kolonić, Slobodanka ; Dominis, Mara
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Chromosome Research
/ Garcia-Sagredo, Jose ; Madan, Kamlesh ; Miller KOnstantin - Dordrecht : Springer, 2011, S144-S144
Skup
8th European Cytogenetics Conference
Mjesto i datum
Porto, Portugal, 02.07.2011. - 05.07.2011
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
FISH; karyotype; PCR; BCR/ABL1
Sažetak
Chronic myelogenous leukemia is characterized by translocation BCR/ABL1 resulting in production of BCR/ABL1 fusion protein – aberrant tyrosine kinase. This specificity allowed development of targeted therapy. In 1990s imatinib mesylate, specific tyrosine kinase inhibitor was produced and till today it is the first line of treatment for majority of patients with confirmed translocation. BCR/ABL1 is most commonly detected by standard karyotyping, while additional methods for its detection are PCR and FISH. Q-PCR is usually used for monitoring differences in amount of BCR/ABL1 transcript during the therapy and defining molecular response to treatment. In period between January 2007 and Jun 2010, nine patients with suspected CML were admitted to our hospital. All had histopatological diagnosis of MPD/CML. Karyotype and PCR were done in order to detect BCR/ABL1 translocation. When this data were taken together with clinical performance, six of them were finally diagnosed as CML positive for BCR/ABL1 and received imatinib mesylate. All six patients responded well to therapy. Those patients were included in subsequent studies where FISH for detection of BCR/ABL1 had to be performed on their FFPE bone marrow trephine samples. Two different probes were used: break-apart probe for BCR gene and fusion probe for BCR/ABL1 translocation. After double blind reading, with 100% concordance, results showed translocation of BCR gene in 3 of 6 cases (50%) and BCR/ABL1 translocation in 6 of 6 cases (100%). This data suggest that, although considered to be supplementary FISH probes for detection of BCR translocation, differently designed probes can not be used exclusively. We recommend usage of fusion probe for screening process in patients with suspected CML and careful evaluation of samples with at least two independent observers.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081873-1891 - Prognostička vrijednost FOXP1 i FOXP3 u B limfoproliferativnim bolestima (Gašparov, Slavko, MZOS ) ( CroRIS)
108-1081873-1893 - Prognostički faktori, dijagnostika i terapija hemoblastoza (Jakšić, Branimir, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Mirjana Mariana Kardum-Paro
(autor)
Slobodanka Ostojić Kolonić
(autor)
Marija Dominis
(autor)
Petra Korać
(autor)
Ružica Lasan Trčić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE